Aytu BioPharmaの空売り状況は、投資家がAytu BioPharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Aytu BioPharma (NASDAQ:AYTU) 株価情報, 空売り情報

Aytu BioPharma

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Inc

AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) reported $3.65 million in sales this quarter. This is a 6.27 percent decrease over sales of $3.89 million the same period last year.

Earnings

News

UAVS

AgEagle Aerial Sys Q1 Sales $3.65M Down From $3.89M YoY

Veteran short seller Jim Chanos on Thursday revealed <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45417306/michael-saylors-bitcoin-strategy-infinite-money-glitch-or-a-reflexive-leverage-bet">a strategic arbitrage trade</a>: long Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), short Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>).
His position targets what he <a href="https://x.com/coinbureau/status/1922951397776974024">described</a> as a widening and unjustified premium on MicroStrategy's stock relative to its Bitcoin holdings.
&#8220;We're buying Bitcoin, selling MicroStrategy stock—an arbitrage play, buying for $1, selling for $2.50,&#8221; Chanos said during the talk. 
He emphasized that the core trade isn&#8217;t based on predicting Bitcoin's price direction but exploiting the spread between MicroStrategy's net asset value (NAV) and its trading price.
&#8220;I don't know where Bitcoin is going.. $100,000, a million, $10,000. I don't know. I don't think anybody else knows,&#8221; he said. "But what I do know is it's generally profitable to short $1 for $2.50 or three dollars."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45449661/eric-trump-bitcoin-accumulation-is-a-race-to-the-top">Eric Trump: Bitcoin Accumulation Is &#8216;A Race To The Top&#8217;</a>
Chanos, who has intermittently held this position over the past few years, criticized what he sees as a flawed narrative among retail investors: buying into corporate structures like MicroStrategy as a proxy for direct Bitcoin exposure. 
"They are basically selling retail investors the idea that we are going to buy Bitcoin in a corporate structure… and therefore earnings are created by the difference between what new investors are paying with the net asset value is,&#8221; he said.
He likened his own approach to that of Strategy founder Michael Saylor saying, "We're doing exactly what MicroStrategy and Michael Saylor are doing," highlighting that his trade simply reverses the structure: directly buying Bitcoin while selling the stock.
Chanos also pointed to the premium to NAV as a barometer of market speculation, noting it has recently returned to levels seen at the end of 2024. 
"It's a good barometer, not only just of the arbitrage itself, but I think of retail speculation," he added.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/top-stories/25/05/45448569/ftx-to-distribute-over-5b-to-creditors-in-second-round-of-payouts-on-may-30">FTX To Distribute Over $5B To Creditors In Second Round Of Payouts On May 30</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Sellers

$BTC

MSTR

Jim Chanos Goes Long Bitcoin, Short MicroStrategy In Arbitrage Bet Against Retail Speculation

Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) reported quarterly losses of $(0.88) per share. This is a 66.41 percent increase over losses of $(2.62) per share from the same period last year. The company reported $5.94 million in sales this quarter. This is a 52.70 percent decrease over sales of $12.55 million the same period last year.

SLNH

Soluna Holdings Q1 EPS $(0.88) Up From $(2.62) YoY, Sales $5.94M Down From $12.55M YoY

UBS analyst Steven Fisher upgrades Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) from Sell to Neutral and raises the price target from $34 to $48.

Upgrades

Price Target

Analyst Ratings

UBS Upgrades Terex to Neutral, Raises Price Target to $48

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency
First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages&nbsp;
Potential First-in-Disease Treatment for ENPP1 Deficiency
Conference Call and Webcast Scheduled Today at 8:45 a.m. ET
SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) and Inozyme Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total consideration of approximately $270 million. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2025, subject to regulatory approval, successful completion of a tender offer and other customary closing conditions.

BMRN

INZY

BioMarin Agrees To Acquire Inozyme For $4.00/Shr In All-Cash Transaction For Total Consideration Of About $270M

UBS analyst Steven Fisher upgrades United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from Sell to Neutral and raises the price target from $485 to $780.

UBS Upgrades United Rentals to Neutral, Raises Price Target to $780

Wedbush analyst, Dan Ives&nbsp;anticipates that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) could increase its&nbsp;iPhone assembly production in India&nbsp;to 60%-65% by fall, depending on tariff negotiations.
What Happened:  On Friday, Ives posted his views on X that Apple could significantly ramp up its iPhone assembly in India in a best-case scenario. However, he also noted that the tech giant could revert to a China-driven iPhone strategy depending on the tariff situation and deal negotiations. He added that U.S. iPhone production is &#8220;not feasible.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We believe Apple could ramp iPhone assembly production in India up to 60%-65% by the Fall in a best case scenario but could easily pivot back to a China driven iPhone strategy depending on the tariff situation and deal negotiations. US iPhone production not feasible &#x1f3c6;&#x1f525;&#x1f402;&#x1f4f1;&#x1f34e;&#x1f34f;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1923306260176294386?ref_src=twsrc%5Etfw">May 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This post comes in the wake of President Donald Trump expressing his disapproval of Apple&#8217;s manufacturing expansion in India. Trump told Apple CEO Tim Cook, &#8220;I don't want you building in India.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45460177/bitcoin-rises-while-ethereum-dogecoin-slip-market-isnt-going-to-peak-in-the-next-6-months-says-popular-analyst" target="_blank" rel="noreferrer noopener">Bitcoin Rises While Ethereum, Dogecoin Slip — &#8216;Market Isn&#8217;t Going To Peak In The Next 6 Months,&#8217; Says Popular Analyst &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fractional undivided benefi</a>
Why It Matters: Despite Trump&#8217;s criticism, India remains committed to its partnership with&nbsp;<a href="https://www.benzinga.com/markets/25/05/45462006/no-change-in-apples-production-plans-says-india-despite-trumps-little-problem-with-ceo-tim-cook-report">Apple</a>. The company has reportedly reassured the Indian government of its commitment to continue using India as a major manufacturing base. This assurance comes despite Trump's recent remarks, with government sources emphasizing that there is "no change" in Apple's investment plans in India.
Apple&#8217;s stock recently saw a boost following a breakthrough in trade negotiations between the&nbsp;<a href="https://www.benzinga.com/news/25/05/45358770/apple-stock-rises-following-us-china-trade-breakthrough">United States and China</a>. The tech giant, heavily reliant on a China-centric supply chain for manufacturing iPhones, was a clear beneficiary of the temporary rollback in tariffs.
Over the past five days, the shares of Apple climbed 6.26%, while on a year-to-date basis, it declined 13.29%, as per data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/general/health-care/25/05/45431505/gop-tax-bill-breaks-trumps-social-security-tax-pledge-still-hits-25-million-seniors-while-elo" target="_blank" rel="noreferrer noopener">GOP Tax Bill Breaks Trump&#8217;s Social Security Tax Pledge, Still Hits 25 Million Seniors While Elon Musk&#8217;s Stock Wealth Skirts FICA</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

AAPL

Apple iPhone Production In US 'Not Feasible,' Says Tech Bull After Donald Trump Tells Tim Cook To Stay Out Of India

GIBO

GIBO Reveals Upcoming Launch Of GIBO Create-to-Earn Module To Empower Monetization Of AI Animation And Creative Content Within Its Ecosystem

UNH climbs over 17 Points after the Alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15202214/Screenshot-2025-05-15-at-4.20.20%E2%80%AFPM-1024x1018.png" alt="" class="wp-image-13011" /></figure>
UnitedHealth Group Inc. (UNH) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:09AM on May 15th, a significant trading signal occurred for UnitedHealth (UNH) as it demonstrated a Power Inflow at a price of $257.20. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in UNHs stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in UNH's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for UNH, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $257.20. The returns on the High price ($275.23) and Close price ($274.35) after the Power Inflow are respectively 7.0% and 6.6%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk. They were close today but that is not always the case.

Equities

WIIM

Technicals

Opinion

Signals

Trading Ideas

Insurance

UnitedHealth Stock Rises 7% After Key Signal

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and lowers the price target from $23 to $15.

LXEO

HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $15

Partnership will build a global AI-powered healthcare platform to deliver more effective, scalable, and affordable care
ABU DHABI, United Arab Emirates, May 16, 2025 /PRNewswire/ -- Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking AI-based healthcare delivery platform. This initiative aims to improve patient care and public health management by leveraging AI, nation-scale data analytics, and intelligent clinical applications to create secure, scalable, and accessible care models that positively impact people's health and longevity.
The platform will serve as the foundation for an AI-driven healthcare hub, combining Oracle Cloud Infrastructure, Oracle AI Data Platform, and Oracle Health applications, Cleveland Clinic's world-class clinical expertise, and G42's capabilities in sovereign AI infrastructure, health data integration, and advanced clinical AI models. Designed to meet the evolving needs of global populations, starting with the U.S. and the United Arab Emirates, the platform will deliver secure, scalable, and intelligent healthcare solutions that enhance patient outcomes, enable precision medicine, and support the transition from reactive treatment to proactive wellbeing.

ORCL

Oracle Health, Cleveland Clinic, And G42 Announce Strategic Partnership To Develop AI-based Healthcare Delivery Platform

UBS analyst Steven Fisher upgrades Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) from Neutral to Buy and raises the price target from $548 to $634.

UBS Upgrades Martin Marietta Materials to Buy, Raises Price Target to $634

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Needham analyst Charles Shi reiterates Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and maintains $195 price target.

Reiteration

AMAT

Needham Reiterates Buy on Applied Mat, Maintains $195 Price Target

UBS analyst Steven Fisher upgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Sell to Neutral and raises the price target from $272 to $357.

UBS Upgrades Caterpillar to Neutral, Raises Price Target to $357

GLPI

Gaming and Leisure Properties Declared Q2 Cash Dividend Of $0.78 Per Share, Marking An Increase Of $.02 Per Share Per Quarter From Prior Level; Dividend Is Payable On June 27

Brady (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) narrows FY2025 Adj EPS guidance from $4.45-$4.70 to $4.48-$4.63 vs $4.58 analyst estimate..

Guidance

CORRECTION: Brady Narrows FY2025 Adj EPS Guidance from $4.45-$4.70 to $4.48-$4.63 vs $4.58 Est

ReAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 100 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $925.63 thousand which beat the analyst consensus estimate of $606.00 thousand by 52.75 percent. This is a 4.43K percent increase over sales of $20.43 thousand the same period last year.

Earnings Beats

Earnings Misses

AIRE

ReAlpha Tech Corp Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $925.63K Beat $606.00K Estimate

Needham analyst Scott Berg maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Buy and lowers the price target from $82 to $67.

DOCS

Needham Maintains Buy on Doximity, Lowers Price Target to $67

SPCE: 30% &#x7C; <a href="https://www.benzinga.com//node/45452248">Virgin Galactic Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.</a>
&nbsp;
TSSI: 71% &#x7C; <a href="https://www.benzinga.com//node/45464391">TSS shares are trading higher after the company reported a year-over-year increase in Q1 revenue results.</a>
&nbsp;
DOCS: -25% &#x7C; <a href="https://www.benzinga.com//node/45464311">Doximity shares are trading lower after the company issued FY26 and Q1 sales guidance below estimates.</a>

Comments

Aytu BioPharma

空売り

Aytu BioPharma (NASDAQ:AYTU) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル